• Explore /
  • Poster
  • / FCN-159, a MEK1/2 inhibitor, in patients with advanced melanoma harboring <em>NRAS</em> or <em>NF1 </em>mutations: A phase 1B dose-expansion study.

FCN-159, a MEK1/2 inhibitor, in patients with advanced melanoma harboring NRAS or NF1 mutations: A phase 1B dose-expansion study.

Abstract Poster

Authors

null

Junjie Gu

Department of Melanoma and Sarcoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China

Junjie Gu , Lili Mao , Jun Guo , Yu Jiang , Lingjun Zhu , Xiaoshi Zhang , Wangjun Yan , Yu Chen , Chang Tan , Weiyou Zhu , Jian Zhang , Jie Liu , Jing Lin , Zhuli Wu , Xingli Wang , Yuchen Yang , Ben Li , Lu Si

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

Small Molecules

Clinical Trial Registration Number

NCT03932253

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 3095)

DOI

10.1200/JCO.2024.42.16_suppl.3095

Abstract #

3095

Poster Bd #

240

Abstract Disclosures

Similar Posters

First Author: Mohammed M. Milhem

First Author: Melinda L. Telli

First Author: Daniel Olson

First Author: Omid Hamid